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monocyte-like cells in lipopolysaccharide-mediated
acute lung inflammation
Mairi Brittan1,5*, Laura C Barr2, Niall Anderson3, Andrew Conway Morris2, Rodger Duffin2, John A Marwick2,
Fiona Rossi2, Shonna Johnson2, Kev Dhaliwal2, Nikhil Hirani2, Adriano G Rossi2 and A John Simpson2,4Abstract
Background: We have previously reported the presence of novel subpopulations of pulmonary monocyte-like cells
(PMLC) in the human lung; resident PMLC (rPMLC, HLA-DR+CD14++CD16+cells) and inducible PMLC (iPMLC, HLA-DR+
CD14++CD16- cells). iPMLC are significantly increased in bronchoalveolar lavage (BAL) fluid following inhalation of
lipopolysaccharide (LPS). We have carried out the first functional evaluation of PMLC subpopulations in the inflamed
lung, following the isolation of these cells, and other lineages, from BAL fluid using novel and complex protocols.
Methods: iPMLC, rPMLC, alveolar macrophages (AM), neutrophils, and regulatory T cells were quantified in BAL
fluid of healthy subjects at 9 hours post-LPS inhalation (n = 15). Cell surface antigen expression by iPMLC, rPMLC
and AM and the ability of each lineage to proliferate and to undergo phagocytosis were investigated using flow
cytometry. Basal cytokine production by iPMLC compared to AM following their isolation from BAL fluid and the
responsiveness of both cell types following in vitro treatment with the synthetic corticosteroid dexamethasone
were assessed.
Results: rPMLC have a significantly increased expression of mature macrophage markers and of the proliferation
antigen Ki67, compared to iPMLC. Our cytokine data revealed a pro-inflammatory, corticosteroid-resistant phenotype
of iPMLC in this model.
Conclusions: These data emphasise the presence of functionally distinct subpopulations of the monocyte/
macrophage lineage in the human lung in experimental acute lung inflammation.
Keywords: Monocytes, Macrophages, Acute lung inflammation, Lipopolysaccharide, Multiparameter flow cytometry,
CorticosteroidBackground
We have recently published data resulting from a rando-
mised controlled trial (RCT) investigating the effects of
mononuclear cell depletion by leukapheresis in healthy
volunteers following lipopolysaccharide (LPS)-mediated
acute lung inflammation [1]. This RCT permitted further
investigation into the properties of novel subpopulations
of pulmonary monocyte-like cells (PMLC) present in the* Correspondence: mbrittan@staffmail.ed.ac.uk
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unless otherwise stated.human lung, as recently reported by our laboratory [2].
PMLC are subcategorised into resident (rPMLC; HLA-
DR+CD14++CD16+) and inducible (iPMLC; HLA-DR+
CD14++CD16-) subpopulations, the latter being signifi-
cantly increased in bronchoalveolar lavage (BAL) fluid
following inhalation of LPS, in parallel with a significant
increase in neutrophils, and a significant decrease in
regulatory T cells [2]. Monocyte-like cells have been de-
scribed in the human lung, with an expansion of this
population in inflammatory lung diseases [3-5]. We
herein report the first functional evaluation of subpopu-
lations of monocyte-like cells present in the inflamed
lung, following the isolation of these cells, and other
lineages, from BAL fluid using novel and complexLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ant given their possible regulatory role in acute lung in-
flammation and their potential as a cellular target for
future therapies. Our original expectation was that
iPMLCs may play a role in coordinating inflammatory
cell recruitment to the lung during acute inflammation,
and in orchestrating the subsequent course of the in-
flammatory response. We speculated that, at least at the
time point studied here, iPMLCs may exhibit a relatively
pro-inflammatory functional response.
We therefore quantified iPMLC, rPMLC, alveolar
macrophages (AM), neutrophils, and regulatory T cells
present in BAL fluid at 9 hours post-LPS inhalation in
control subjects who participated in our RCT (i.e. those
subjects who inhaled LPS and were then randomised to
receive “sham” leukapheresis, n = 15). Characterisation
of cell surface antigen expression by iPMLC, rPMLC
and AM using polychromatic flow cytometry, and the
ability of each lineage to proliferate and to undergo
phagocytosis were investigated. We also assessed basal
cytokine production by iPMLC compared to AM follow-
ing their isolation from BAL fluid using fluorescence-
activated cell sorting (FACS), and the responsiveness of
both cell types following in vitro treatment with the syn-
thetic corticosteroid dexamethasone.
Methods
Subjects and study protocol
Details of the RCT including subject demographics are
described elsewhere [1]. For this component of the
study, healthy male non-smokers aged 18-40 (n = 15) in-
haled 60 μg LPS (from Escherichia coli 026:B6, L2654;Table 1 Primary antibodies used for flow cytometry and FACS
Fluorochrome-conjugated antibody Clone
PMLC and Macrophages
Anti-human (h)CD14 PerCP/Cy5.5 HCD14
Anti-hCD16 PE/Texas Red 3G8
Anti-hHLA-DR V450 G46-6
Anti-hCD206 PE 15-2
Anti-hCD163 APC GHI/61
Anti-hKi-67 PE Ki-67
Anti-hCD71 FITC CY1G4
Anti-human mature macrophage marker (25 F9) APC eBio25 F9
Regulatory T cells
Anti-hCD3 FITC UCHT1
Anti-hCD4 APC/Cy7 RPA-T4
Anti-hCD25 PE BC96
Anti-hCD127 PE/Cy5 eBioRDR5
Staining panels were prepared using specific combinations of antibodies in order to
isothiocyanate; PE = phycoerythrin; APC = allophycocyanin.Sigma, Poole, UK) using an inhalation-synchronised
dosimeter nebuliser (Spira Elektro 2, Hameenlinna,
Finland) as described [6], and were then randomised to
receive sham leukapheresis of 4 total blood volumes
2 hours later using the COBE SPECTRA Apheresis System
MNC Program (version 4.7) (CaridianBCT, Lakewood,
CO, USA). Bronchoscopy and BAL were performed at
9 hours [2,6].
This research was carried out in compliance with the
Helsinki Declaration and was approved by the Lothian
research ethics committee and the NHS Lothian/Univer-
sity of Edinburgh Research and Development Office,
Edinburgh, UK.Flow cytometry
BAL fluid cells were washed in phosphate-buffered sa-
line (PBS) and resuspended at 1 × 106 cells/ml in 0.1%
bovine serum albumin (BSA) in PBS with Ca2+/Mg2+.
Cells (1 × 105 per sample) were incubated for 40 minutes
at 4°C with antibodies against specific cell surface anti-
gens (Table 1). Unstained cells, single antibody stains
and fluorescence minus-one (FMO) controls were used.
Erythrocytes were lysed using FACS Lysing Solution (BD
Biosciences, San Jose, CA, USA) (20 minutes, 20°C).
Samples were washed in PBS, centrifuged and resus-
pended for analysis using a BD SORP LSRFortessaII cell
analyser with FACSDiva software (BD Biosciences).
Anti-mouse Ig BD CompBeads™ were used to calculate
automatic compensations; these were also verified manu-
ally for each antibody. FlowJo version 9.2 (TreeStar, OR,
USA) was used for data analysis.Manufacturer, catalogue number Laser filter, bandpass
BioLegend, 325622 Blue, 695/40
Invitrogen, MHCD1617 Yellow/green (Y/G), 610/20
BD Horizon, 561359 Violet, 450/50
BioLegend, 321105 Y/G, 582/15
BioLegend, 333609 Red, 670/30
BioLegend, 350504 Y/G, 582/15
BioLegend, 334104 Blue, 530/30
eBioscience, 14-0115-82 Red, 670/30
BD Pharmingen, 555332 Blue, 530/30
BioLegend, 300518 Red, 780/60
BioLegend, 302606 Y/G, 582/15
eBioscience, 15-1278-42 Y/G, 670/30
analyse multiple cell subpopulations within a single sample. FITC = fluorescein
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dexamethasone treatment of AM and iPMLC in vitro
In order to isolate iPMLC and AM from BAL fluid using
FACS, the remaining BAL cells were incubated with the
relevant antibodies (Table 1) for 30 minutes at 4°C,
washed in PBS and resuspended in 1% autologous serum
in PBS. A BD FACSAriaII cell sorter was used with
FACSDiva software (BD Biosciences). Sorted cells were
collected into 10% autologous serum in PBS and a small
proportion was analysed to assess the purity of the iso-
lated population. Samples of less than 95% purity were
discarded. Cells were incubated under standard cell cul-
ture conditions with and without 100 nM dexametha-
sone for 24 hours. Cell supernatants were extracted and
a BD Cytometric Bead Array (BD Biosciences, San Diego,
CA, USA) was used to measure the concentration of a
number of cytokines.Phagocytosis
pHrodo™ Red E. coli BioParticles® (Life Technologies,
UK) were incubated with E. coli BioParticles® opsonising
reagent (Life Technologies, UK) for 1 hour (37°C) and
then washed twice in PBS using centrifugation for 5 mi-
nutes at 300 g (4°C). BAL cells were placed on ice for
10 minutes and were then incubated for 15 minutes at
4°C or 37°C with either the opsonised E. coli BioParti-
cles® or PBS control, as per the manufacturer’s instruc-
tions. Following the recommended lysis and wash steps,
the samples were re-suspended in FACS Lysing Solution
and analysed using a BD SORP LSRFortessaII cell
analyser.Statistical analyses
GraphPad Prism (version 6, GraphPad Software Inc.,
CA, USA) was used for data analysis. Normally dis-
tributed data were analysed by unpaired t-test with
Welch’s correction and expressed as mean (SD). Data
that were not normally distributed were expressed as
median [interquartile range] and were analysed by Mann
Whitney U test. A P value of <0.05 was considered
significant.Figure 1 Cytocentrifuge preparations of cells in BAL fluid following L
(D) and alveolar macrophages (AM) (E) were isolated from BAL fluid with h
monocytes and are a similar size to neutrophils, larger than lymphocytes a
of each lineage were observed i.e. multi-lobular neutrophils, lymphocytes wResults
Cellular composition of BAL fluid
One subject did not undergo bronchoscopy and BAL as
his forced expiratory volume in 1 second (FEV1) had
fallen by >10% from baseline (a pre-defined safety criter-
ion). Figure 1 shows cytocentrifuge preparations of
iPMLC, rPMLC, neutrophils, lymphocytes, and AM iso-
lated from BAL fluid with greater than 95% purity by
FACS, in order to investigate the morphology and size of
each cell population. The gating strategies used to iden-
tify cell subpopulations within BAL fluid using flow cy-
tometry and for FACS isolation are outlined in Figure 2.
The proportion of iPMLC (HLA-DR+CD14++CD16-) was
significantly higher than rPMLC (HLA-DR+CD14++
CD16+) in BAL fluid (expressed as mean (SD) % of total
PMLC in BAL fluid, n = 14; iPMLC 91.2 (3.9); rPMLC
8.8 (3.9); P < 0.0001, unpaired t-test) (Table 2).
Macrophage phenotype and proliferative capacity of
PMLC subpopulations
Polychromatic flow cytometry was used to assess the
phenotype and proliferative capacity of PMLC subpopu-
lations in BAL fluid. In comparison with rPMLC, iPMLC
had a significantly lower expression of the proliferation
marker, Ki67, the transferrin receptor, CD71 and the
macrophage mannose receptor, CD206. The scavenger
receptor, CD163 and the mature macrophage marker,
25 F9, were expressed by a lower proportion of iPMLC
compared to rPMLC, although this was not significant
(Table 3).
Phagocytosis
Alveolar macrophages had a significantly increased abil-
ity to undergo phagocytosis compared to PMLC in BAL
fluid (Figure 3).
Cytokine production and response to dexamethasone by
iPMLC and AM
iPMLC and AM were isolated from BAL fluid with high
purity using FACS (Figure 2). Cells were grown in stand-
ard cell culture conditions with or without dexametha-
sone treatment (100 nM for 24 hours). There was noPS inhalation. iPMLC (A), rPMLC (B), neutrophils (C), lymphocytes
igh purity using FACS. PMLC are similar in morphology to blood
nd smaller than AM (Scale bar = 20 μm). Typical morphological features
ith high nucleus to cytoplasm ratio, and “fried egg”-shaped AM.
Figure 2 Fluorescence activated cell sorting of cells in BAL fluid following LPS inhalation. Cells were identified in BAL fluid based upon
their position on flow cytometry dot plots of size i.e. forward scatter (FSC-A) versus granularity i.e. side scatter (SSC-A) (A). PMLC were selected as
HLA-DR + (B), and were subdivided into iPMLC and rPMLC subpopulations based upon their CD14 and CD16 expression (CD14++CD16- and
CD14++CD16+, respectively; C). Representative samples of AM, iPMLC and rPMLC isolated from BAL fluid using FACS with >95% purity, and
overlapped on SSC-A versus FSC-A dot plots are seen in (D). Like PMLC, it was possible to identify distinct populations of lymphocytes, neutrophils and
alveolar macrophages in BAL fluid following LPS inhalation based upon their size and granularity (A). Lymphocytes were further selected for CD3
expression (E), neutrophils were classed as CD16+ HLA-DR- (F) and AM were selected as large CD16+ HLA- DR + cells (G).
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(IL)-6, IL-8 or tumour necrosis factor-alpha (TNFα) pro-
duction (pg cytokine per 10,000 cells) by iPMLC com-
pared to AM, following isolation from BAL fluid and
in vitro growth for 24 hours (n = 8, Figure 4). However a
trend towards a difference in responsiveness to cortico-
steroid treatment was observed. Dexamethasone signifi-
cantly suppressed IL-8 and IL-6 secretion by AM, with a
trend towards suppression of TNFα secretion. In con-
trast, dexamethasone did not significantly suppress cyto-
kine secretion by iPMLC after 24 hours of treatment
(Figure 4).
Discussion
Measures of LPS-induced inflammation were broadly con-
sistent with our previous study, where subjects inhaledTable 2 Cellular composition of cells present in BAL fluid
Cell type Proportion present in BAL fluid
(mean (SD) % total cells)
PMLC 17.8 (7.2)
Alveolar macrophages 26.4 (11.0)
Neutrophils 23.2 (11.0)
Lymphocytes 20.0 (10.5)
Data are expressed as mean (SD) % of total cells in BAL fluid (n = 14).LPS but did not undergo active/sham leukapheresis [2],
and therefore it is unlikely that cells present in BAL fluid
of the subjects involved in this study were altered or acti-
vated, or that measures of inflammation were significantly
changed by sham leukapheresis. Sham leukapheresis has
been shown to have no effect on monocyte chemotaxis or
migration [7].
Our original classification of inducible and resident
PMLC subpopulations was based upon the variable ex-
pression of the monocyte markers CD14 and CD16, and
the clear shift in the ratio of these cells in LPS-mediated
experimental acute lung inflammation. We previously
postulated that iPMLC may be sequestered from the cir-
culation alongside neutrophils during self-limiting lung
inflammation and, in contrast, that rPMLC were en-
dogenous to the lung and contributed to macrophage
homeostasis i.e. by undergoing proliferation and macro-
phage differentiation [2]. Our observation in the current
study that rPMLC have a significantly increased expres-
sion of the mature macrophage markers CD206 (man-
nose receptor), CD71 (transferrin receptor) and 25 F9
(mature macrophage marker) and a significantly in-
creased expression of the proliferation antigen Ki67,
compared to iPMLC, is broadly supportive of our previ-
ous hypothesis, although this cannot be proven defini-
tively, given the limitations and the nature of the current
Table 3 Cell surface antigen expression by PMLC subpopulations in BAL fluid following LPS inhalation
ANTIGEN EXPRESSED BY rPMLC iPMLC
Ki67 Proliferating cells 19.0 [18.5 – 42.1] 2.1 [0.7 – 8.4]**
CD71 (transferrin receptor) Mature macrophages 20.3 [15.7 – 31.7] 2.8 [1.5 – 3.6]***
CD206 (mannose receptor) Alternatively activated macrophages 86.7 [72.8 – 97.9] 61.9 [40.6 – 73.9]*
CD163 Alternatively activated macrophages 92.2 [56.4 – 98.5] 69.6 [29.1 – 91.9]NS
25 F9 Mature macrophages 89.8 [73.1 – 97.0] 57.3 [14.4 – 97.5]NS
Data are expressed as median [interquartile range (IQR)] % of cells expressing each marker; n = 12; statistical analysis by Mann Whitney U test; NSnon-significant,
*P < 0.05, **P < 0.005, ***P < 0.0005.
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like phenotype and have a significantly lower proliferative
capacity compared to rPMLC. Therefore, it seems unlikely
that the primary function of iPMLC is to contribute to re-
generative demand and cellular turnover, and our data
suggest that a pro-inflammatory function is more likely at-
tributable to these cells, at least at the time point studied.
This is supported by our cytokine data.
There are a number of limitations to this study that
merit discussion. These principally stem from two prob-
lems. Firstly, flow sorting of cells from complex inflam-
matory populations in the human lung inevitably yields
a relatively small and finite number of cells for study.
Secondly, repeat bronchoscopy on the same day raises
considerable ethical issues, and bronchoalveolar lavage
itself leads to an inflammatory response in the lung after
the procedure – these considerations inevitably meant
that we could only study one time point in the process,
and no inferences can be made regarding the time
course and dynamics of any of the processes studied.Figure 3 Phagocytosis by cells in BAL fluid. Alveolar macrophages
displayed a significantly increased capacity for phagocytosis compared
to PMLC (P =0.0006 by Mann Whitney U test (n = 13)).As such, due to the low numbers of rPMLC present in
BAL fluid in this model it was not possible to isolate
these cells by FACS in order to determine their basal
cytokine production or response to steroid treatment, al-
though this would be of interest for future studies. Due
to the technical complexities associated with using FACS
to isolate highly pure cell subpopulations from BAL fluid
for in vitro growth and treatment with dexamethasone
(i.e. samples of less than 95% purity were discarded), it
was only possible to grow sorted cell populations from 8
of out 14 subjects. Notably, we were still able to demon-
strate a significant response by AM to dexamethasone
treatment, whereas iPMLC did not show any response
to dexamethasone. The phagocytic capacity of individual
PMLC subpopulations is of interest, although it was not
possible to determine this due to limitations in the assay
conditions. It is important to highlight that, despite sig-
nificant differences in cell surface antigen expression by
iPMLC and rPMLC, a degree of heterogeneity exists
within both PMLC subpopulations, and it is plausible
that functional crossover may occur. We have previously
reported differential cell counts from cytocentrifuge
preparations of BAL fluid from subjects who have in-
haled LPS and then undergone active leukapheresis
compared to those receiving sham leukapheresis [1],
which was in accordance with the secondary endpoint of
our RCT of pulmonary neutrophilia in BAL fluid. A dis-
crepancy exists in the reported cellular composition of
BAL fluid when comparing data from cytocentrifuge
preparations compared to lineage analysis using poly-
chromatic flow cytometry reported herein. However, we
have shown that PMLC subpopulations are similar to
lymphocytes and neutrophils in size, and it may be diffi-
cult to consistently distinguish PMLC from other line-
ages using cytocentrifuge preparations alone. Our data
show that PMLC represent a significant proportion of
the cells present in BAL fluid following LPS inhalation,
similar in number to neutrophils at 9 hours. This obser-
vation was unexpected and implies that PMLC may play
a significant role in the acute inflammatory response. It
also implies that future studies of the cell content of
BAL fluid should consider using flow cytometry to quan-
tify the cellular composition of BAL fluid, taking into
Figure 4 In vitro cytokine production by AM and iPMLC in response to treatment with dexamethasone. Log concentrations of IL-6 (Panels A-B),
IL- 8 (Panels C-D) and TNFα (Panels E-F) in supernatants from flow-sorted, cultured AMs and iPMLCs. Data are shown paired (with/without incubation
with dexamethasone) per 10,000 cells cultured; n = 8; statistical analysis was by Wilcoxon signed rank test; *P < 0.05.
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cols described herein.
Experimental inhalation of LPS models some of the
early features of acute lung injury (ALI) such as neutro-
philia in peripheral blood and in the alveolar space, and
protein leak across the alveolar-capillary membrane. The
use of corticosteroids to treat ALI, and the optimal tim-
ing of administration, remains extremely controversial
[8-11], and we felt it would be relevant to assess
corticosteroid-responsiveness in distinct cell populations
isolated from BAL fluid in volunteers who had inhaledLPS. iPMLC produced comparable concentrations of the
inflammatory cytokines IL-6, IL-8 and TNFα compared
to AMs, yet displayed a significantly reduced responsive-
ness to dexamethasone. Our data suggest that cortico-
steroids may potentially down-regulate secretion of
inflammatory cytokines from AMs, but are unlikely to
influence cytokine release from iPMLC. However, as dis-
cussed previously, the time point selected for study
could have influenced these results. The BAL cells were
collected at 9 hours after inhalation of LPS and the
addition of dexamethasone was thus commenced at a
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in dexamethasone-induced suppression of cytokine re-
lease observed between AM and iPMLC reflects a differ-
ence in the timing of peak cytokine release by both cell
types. Corticosteroids inhibit apoptosis of neutrophils
[12], the predominant alveolar cell in ALI, and this has
been proposed as a potential reason for lack of thera-
peutic efficacy in this setting. In the current study we
did not have sufficient cells to determine whether corti-
costeroids directly affect apoptosis of AMs and iPMLCs,
and we recognise that any such effect could influence
our findings.
In summary, our data show that after LPS challenge
iPMLC constitute a significant proportion of the cellular
component of BAL fluid. iPMLC have a low capacity for
proliferation or phagocytosis and are capable of produc-
tion of similar, albeit low, levels of pro-inflammatory cyto-
kines compared to AM. Interestingly, unlike AM, iPMLC
appear to be unaffected by corticosteroid treatment
in vitro, at least in our experimental system. Further data
are clearly required to understand the physiological or
pathological relevance of these cells, and to determine
whether their function and phenotype change as the in-
flammatory process proceeds. Nevertheless, we believe
our findings represent a useful first step, suggesting the
potential for iPMLC to play a role in the early regulation
of inflammatory responses in the human lung.
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